Crystalline Leflutrozole Form A for Sustained Testosterone Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for testosterone deficiency, particularly in hypogonadotropic hypogonadism, are inconvenient and limited, often requiring frequent visits to healthcare providers and daily applications, necessitating a more effective treatment option.
Innovation Solution
Development of crystalline Form A of leflutrozole, characterized by specific X-ray powder diffraction peaks, differential scanning calorimetry endotherms, and infrared spectroscopy absorbances, which is formulated into pharmaceutical compositions for oral or intravenous administration, providing a new treatment option for hypogonadism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If intramuscular injections of testosterone are administered every 2 to 4 weeks, then testosterone levels are maintained, but frequent visits to healthcare providers are required
Solution Approach 1:
The patent changes the chemical structure parameter by introducing a fluorine atom at the 4-position of the letrozole molecule to create leflutrozole. This structural modification extends the drug's duration of action, allowing for less frequent administration (every 2-4 weeks) while maintaining effective testosterone levels, thereby reducing the time loss associated with frequent healthcare visits
2Duration of action of stationary object
If testosterone gels or patches are applied daily, then testosterone levels are maintained, but daily application is required
Solution Approach 1:
The patent modifies the chemical parameters of the aromatase inhibitor by fluorination, which extends the drug's half-life and duration of action. This allows for less frequent administration intervals (every 2-4 weeks instead of daily), significantly improving ease of operation by eliminating the need for daily application while maintaining effective testosterone levels
3Reliability
If letrozole is used for aromatase inhibition, then estradiol conversion is blocked, but crystalline form and bioavailability are limited
Solution Approach 1:
The patent changes the chemical structure parameter by introducing a fluorine atom at the 4-position of letrozole, creating leflutrozole with improved crystalline properties and bioavailability. This structural modification maintains reliable aromatase inhibition efficacy while improving ease of manufacture through better crystalline form availability and solubility characteristics
Solution Approach 2:
The patent develops pharmaceutical compositions containing leflutrozole in specific crystalline forms combined with excipients and formulation agents. These composite materials optimize both the reliability of aromatase inhibition and the ease of manufacture by improving crystalline form stability, solubility, and bioavailability while maintaining therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Crystalline Form A of leflutrozole effectively increases testosterone levels, reduces estradiol levels, and normalizes luteinizing hormone and follicle stimulating hormone levels, improving fertility and sexual health without daily applications.
Implementation Method 1
Leflutrozole is a selective, non-steroidal, and reversible aromatase inhibitor which blocks the aromatase enzyme (CYP19), thereby restricting the conversion of testosterone to estradiol and androstenedione to estrone
Data Source
AI summary
The present disclosure relates to crystalline forms of leflutrozole and methods to prepare crystalline leflutrozole, in one of several forms and of high purity. Also provided are compositions comprising crystalline leflutrozole, and use of the crystalline leflutrozole compounds or compositions in methods of treating disease in subjects in need thereof.